Data on clinical characteristics of nonalcoholic fatty liver disease (NAFLD) in patients with chronic kidney disease (CKD) are scarce. We investigated the clinical features and risk factors of NAFLD using noninvasive serum markers in CKD patients and attempted the temporal validation of a predictive model for CKD based on NAFLD. This retrospective cross-sectional study was conducted in a single tertiary center. We enrolled 819 CKD patients and evaluated the predictive performance of relevant clinical and laboratory markers for the presence of NAFLD in both derivation (data from 2011 to 2014, n = 567) and validation (data from 2015 to 2016, n = 252) groups. In the derivation group, NAFLD was observed in 89 patients (15.7%; mean body mass index (BMI), 24.6 kg/m2; median estimated glomerular filtration rate (eGFR), 28.0 ml/min). BMI, hemoglobin, serum alanine aminotransferase, eGFR, and triglyceride-glucose index were used to derive a prediction model for the presence of NAFLD. Using the cutoff value of 0.146, the area under the receiver operating characteristic curve (AUROC) for the prediction of NAFLD was 0.850. In the validation group, NAFLD was observed in 51 patients (20.2%; mean BMI, 25.4 kg/m2; median eGFR, 36.0 ml/min). Using the same prediction model and cutoff value, the AUROC was 0.842. NAFLD prevalence in CKD patients was comparable to that in the general population, increasing over time. Our model using BMI, renal function, triglyceride-glucose index, serum alanine aminotransferase, and hemoglobin accurately predicted the presence of NAFLD in CKD patients.

中文翻译：

---

预测慢性肾病患者非酒精性脂肪肝的无创指标。


慢性肾病（CKD）患者非酒精性脂肪肝（NAFLD）临床特征的数据很少。我们使用 CKD 患者的无创血清标志物研究了 NAFLD 的临床特征和危险因素，并尝试对基于 NAFLD 的 CKD 预测模型进行时间验证。这项回顾性横断面研究是在一个三级中心进行的。我们招募了 819 名 CKD 患者，并评估了衍生组（2011 年至 2014 年的数据，n = 567）和验证组（2015 年至 2016 年的数据，n = 252）中相关临床和实验室标志物对 NAFLD 存在的预测性能。在衍生组中，89 名患者观察到 NAFLD（15.7%；平均体重指数 (BMI)，24.6 kg/m2；中位估计肾小球滤过率 (eGFR)，28.0 ml/min）。 BMI、血红蛋白、血清丙氨酸转氨酶、eGFR 和甘油三酯-葡萄糖指数被用来推导出 NAFLD 存在的预测模型。使用 0.146 的截止值，预测 NAFLD 的受试者工作特征曲线下面积 (AUROC) 为 0.850。在验证组中，51 名患者观察到 NAFLD（20.2%；平均 BMI，25.4 kg/m2；中位 eGFR，36.0 ml/min）。使用相同的预测模型和截止值，AUROC 为 0.842。 CKD 患者中 NAFLD 的患病率与普通人群相当，且随着时间的推移而增加。我们的模型使用 BMI、肾功能、甘油三酯-葡萄糖指数、血清丙氨酸氨基转移酶和血红蛋白准确预测 CKD 患者是否存在 NAFLD。